2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2675

Oral and Gut Microbiota Influence Immune Responses to Sjogren’s Syndrome Associated Antigen Ro60
Abstract Number: 2224

Oral Contraceptive Pill Use in Women with Ankylosing Spondylitis Is Associated with a Younger Age At Diagnosis
Abstract Number: 389

Oral Glucocorticoid Sparing Effects of Rituximab in Rheumatoid Arthritis Patients Who Have Switched from an Anti-TNF Therapy – an Administrative Claims Database Analysis
Abstract Number: 2471

Oral Glucosamine Sulphate for the Prevention of Knee Osteoarthritis in Overweight Females; The First Ever Preventive Randomized Controlled Trial
Abstract Number: 2090

Orchestrating the Orchestrators: Blockade of Flt3L Signaling-Dependent Dendritic Cells Protects Against Collagen Induced Arthritis
Abstract Number: 1164

Orofacial Anomalies in Children with Confirmed Juvenile Idiopathic Arthritis
Abstract Number: 2017

Orthopaedic Treatment of Temporomandibular Joint (TMJ) Damage in Adolescents with Juvenile Idiopathic Arthritis (JIA): Longitudinal Evaluation
Abstract Number: 1235

Orthopedic Surgery Among Patients with Rheumatoid Arthritis 1980-2007: A Population-Based Study to Identify Predictors of Large Joint Vs Small Joint Surgeries
Abstract Number: 1631

Osteoarthritis-Associated Basic Calcium Phosphate Crystals Induce IL-1β, IL-18 and S100A8 Production in a Tyrosine Kinase Dependent Manner
Abstract Number: 20

Osteoclastogenesis Is Inhibited by Immune Complexes Through Activating Fcγ Receptors
Abstract Number: 825

Osteoporosis and Vertebral Fractures Are Important Determinants of Cardiovascular Disease in Rheumatoid Arthritis
Abstract Number: 2359

Outcome of Aortic Involvement in GIANT CELL Arteritis (GCA) After 1-Year Follow-up: Prospective Study in 35 Patients Using Computed Tompography Angiography (CTA)
Abstract Number: 208

Outcome of Muscle Function and Disease Activity in Patients Recently Diagnosed with Polymyositis and Dermatomyositis – Preliminary Results of a 1-Year Follow-up Registry Study
Abstract Number: 2266

Outcome of Renal Transplantation in Lupus Patients with Positive and Negative Serology: Survival of the Graft and Patients After Transplant
Abstract Number: 2617

Outcomes Associated with Belimumab in Black/African American Patients with Systemic Lupus Erythematous in Clinical Practice Settings in the United States

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].